NEW DELHI : NEW DELHI: Bharat Serums and Vaccines Ltd will soon start clinical trial of ulinastatin for treatment of covid-19 patients who have mild-to-moderate acute respiratory distress syndrome (ARDS), managing director and chief executive officer Sanjiv Navangul told Mint in an interview.“The first patient will be enrolled in late June or early July, and it’s a 120-patient trial...
All put together it will take six to eight months for us to get data out of the trial," Navangul said.The trial will be conducted across the country at six-eight centres, he said.The biopharmaceutical company has received approval from Drug Controller General of India V.G.